α1a‐Adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy
Open Access
- 19 July 1996
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 118 (6), 1403-1408
- https://doi.org/10.1111/j.1476-5381.1996.tb15552.x
Abstract
1 Two restriction fragment length polymorphisms of the human α1a-adrenoceptor gene digested with PstI restriction enzyme exist; the nucleotide change causes the substitution of C residue for T at nucleotide 1441, thereby Arg492 to Cys492 transition, which might confer an additional putative palmitoylation site in the carboxy-terminal segment of the α1a-adrenoceptor. In the present study, we compared their pharmacological properties and examined whether this α1a-adrenoceptor polymorphism is associated with benign prostatic hypertrophy (BPH). 2 The frequency of α1a-adrenoceptor polymorphism was not differently distributed between patients with benign prostatic hypertrophy (BPH) and normal subjects in Japan; thus, the relative frequencies of the C and T alleles were 0.90: 0.10 in normal male subjects (n = 45) and 0.87: 0.13 in BPH patients (n = 222), respectively. However, the frequency distribution of this polymorphism was significantly different between the Japanese and U.S. populations; thus, C and T alleles were 0.34 and 0.66 in U.S. populations. 3 Utilizing Chinese hamster ovary (CHO) cells stably expressing the two polymorphic α1a-adrenoceptors (Arg492 and Cys492), we compared their binding affinity and signal transduction. Radioligand binding studies with 2-[β-(4-hydroxy-3[125I]-iodophenyl) ethylamino-methyl]tetralone ([125I]-HEAT) showed no marked difference in the antagonist or agonist binding affinities between the two receptors. Also, both receptors were found to be coupled to the calcium signaling, and the concentration-cytosolic Ca2+ concentrations ([Ca2+]i response relationships for noradrenaline were similar for the two polymorphic receptors. Furthermore, the receptor-mediated [Ca2+]i response was markedly desensitized after a 2 h exposure of phenylephrine (10 μm), and the extent of the desensitization was not significantly different between the two receptors. 4 In summary, the results showed that the two α1a-adrenoceptors generated by genetic polymorphism have similar pharmacological characteristics, and the receptor-mediated [Ca2+]i response can be desensitized in a similar manner. The study did not provide any evidence to support the hypothesis that α1a-adrenoceptor gene polymorphism is associated with BPH.Keywords
This publication has 31 references indexed in Scilit:
- Constitutive activation of cyclic AMP but not phosphatidylinositol signaling caused by four mutations in the 6th transmembrane helix of the human thyrotropin receptorFEBS Letters, 1994
- The pharmacological profile of cloned and stably expressed α1B-adrenoceptor in CHO cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Fluorescence Studies of the Location and Membrane Accessibility of the Palmitoylation Sites of RhodopsinBiochemistry, 1994
- A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious pubertyNature, 1993
- Cloning, Functional Expression and Tissue Distribution of Human cDNA for the α1C-Adrenergic ReceptorBiochemical and Biophysical Research Communications, 1993
- Differential expression of the α1C adrenergic receptor subtype in rat tissuesNeuroReport, 1993
- A two-allele Pstl RFLP for the alpha-1C adrenergic receptor gene (ADRA1C)Human Molecular Genetics, 1992
- A System for Rapid DNA Sequencing with Fluorescent Chain-Terminating DideoxynucleotidesScience, 1987
- LIGAND: A versatile computerized approach for characterization of ligand-binding systemsAnalytical Biochemistry, 1980
- Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder NeckBritish Journal of Urology, 1975